Tumor News and Research

RSS

Herceptin shows real promise in treatment of HER-2 positive breast disease

According to a study conducted at The University of Texas M. D. Anderson Cancer Center, more than twice as many women with early stage, HER-2 positive breast disease who received Herceptin as part of their pre-surgery chemotherapy had their tumors completely disappear compared to like patients who received only chemotherapy.

7 Jun 2004

Gemcitabine may help breast cancer patients with advanced disease live longer

Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study presented today at the American Society of Clinical Oncology (ASCO) annual meeting.

6 Jun 2004

Multi-targeted anticancer drug shows promise as treatment for metastatic renal cell cancer

A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers.

6 Jun 2004

Velcade major improvement over standard therapy for relapsed multiple myeloma

Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.

6 Jun 2004

High school student makes significant contribution to breast cancer research

A high school student from Albany, New York, has made a significant contribution toward understanding how mutations to a gene called BRCA-1 contributes to hereditary breast cancer.

5 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004

Drug helps patients with metastatic colorectal cancer

A drug designed to cut off a tumor’s blood supply, when paired with a chemotherapy combination, resulted in significant improvement in survival in patients with metastatic colorectal cancer, the first time in decades that survival times have been extended in patients with this devastating form of advanced cancer.

3 Jun 2004

Drug to extend lives of colorectal cancer patients

A drug designed to cut off a tumor's blood supply, when paired with a chemotherapy combination, resulted in significant improvement in survival in patients with metastatic colorectal cancer, the first time in decades that survival times have been extended in patients with this devastating form of advanced cancer.

2 Jun 2004

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.

2 Jun 2004

Innovative type of brain scan can determine where blockages of blood to the brain lie

It's a no-brainer that the brain needs a constant supply of blood to keep it going. But some medical conditions can block or reduce that life-giving flow. Whether it's a stroke, a clogged artery or a brain tumor, any situation where blood can't get to the whole brain can lead to death or permanent disability.

2 Jun 2004

Understanding focal adhesion kinase (FAK) may lead to new cancer treatments

Scientists at the University of North Carolina at Chapel Hill have found an unexpected way to turn off a cellular enzyme involved in the progression of several types of human cancers.

2 Jun 2004

Double-punch approach to vaccine design more effective

A study revealing new information about how viral proteins move between cells and alert the immune system suggests that a double-punch approach to vaccine design would make them more effective.

1 Jun 2004

Novel molecular targeting technologies to deliver gene-silencing therapy

Researchers have combined novel molecular targeting technologies to deliver gene-silencing therapy specifically to tumor cells shielded by a normally impermeable obstacle, the blood brain barrier.

1 Jun 2004

Discovery of a key marker in breast cancer tumors

Cancer researchers at Georgetown University Medical Center have discovered a key marker in breast cancer tumors that may help determine which women with early stage breast cancer have a better chance of survival. The research appears in the June 1 issue of the Journal of Clinical Oncology.

31 May 2004

Physicians need to understand comorbidities to better help cancer patients

Findings from a new cancer study may seem obvious — a patient’s overall health is a critical factor in assessing prognosis. But the study’s authors say data about patients’ non-cancer ailments, called comorbidities, are not currently incorporated into cancer statistics.

27 May 2004

Clinical trial of 5 day treatment for earliest form of breast cancer

Researchers at Virginia Commonwealth University’s Massey Cancer Center have begun a clinical trial testing the effectiveness of an established balloon catheter radiation delivery device on the earliest form of breast cancer, ductal carcinoma in situ.

27 May 2004

New target of a cancer-causing gene

Researchers from the Johns Hopkins Bloomberg School of Public Health and other institutions have identified a new target of a cancer-causing gene.

27 May 2004

New technology gives neurosurgeons real-time images in the operating room

Within the past decade, imaging systems have provided much clearer pictures of the brain’s structures, and navigational tools have helped physicians map direct approaches, minimize points of entry and spare healthy brain and function.

27 May 2004

Evidence that abnormally short telomeres play a role in the early development of cancer

Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that abnormally short telomeres - the end-caps on chromosomes that normally preserve genetic integrity -appear to play a role in the early development of many types of cancer.

27 May 2004

Men with low prostate specific antigen levels on screening tests can still have prostate cancer

Men with low PSA (prostate specific antigen) levels on screening tests can still have prostate cancer, according to a study* released today by scientists from the National Cancer Institute (NCI).

27 May 2004